[Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin].
Heinemann
L
L
Profil Institut für Stoffwechselforschung GmbH, Neuss. Lutz.Heinemann@profil-research.de
Heise
T
T
D001682:Biological Availability; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D061267:Insulin Aspart; D000069036:Insulin Glargine; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D008657:Metabolic Clearance Rate / Q000502:physiology
D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine; D061267:Insulin Aspart